Natera Inc.
Natera Reports Strong First Quarter 2024 Financial Results
Summary
Natera, Inc. announced its first quarter 2024 financial results, reporting total revenues of $367.7 million, a 52.1% increase from the prior year. The company processed approximately 735,800 tests, reflecting a 17.5% growth. Gross margins improved to 56.7%, and the company achieved positive cash flow of approximately $3.0 million. Notable achievements include the launch of a fetal RhD NIPT test and the publication of significant data in oncology and organ health.
Profitelligence Alerts
Get alerts for NTRA
Be first to know when Natera Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Official SEC Documents
Advertisement